From Pharmacist to Drug Hunter: A Glimpse Into My Personal Journey-2018-02-15

Event Information
Event Name: 
From Pharmacist to Drug Hunter: A Glimpse Into My Personal Journey
Event Date: 
02/15/2018 - 6:30pm
Event Location: 
Sheppard Mullin, 379 Lytton Ave, Palo Alto, CA 94301
Event Details
Event Type: 
Lecture
Event Details: 

EPPIC GLOBAL Presents

Intrapreneur Spotlight Event

"From Pharmacist to Drug Hunter: A Glimpse Into My Personal Journey"

Speaker: Sharath Hegde, Ph.D.
Senior Vice President and Head of Research
Theravance Biopharma, Inc.
>
>
> Dr. Sharath Hegde will present a talk about his personal journey on February 15, 2018.
>
>
> Sharath S. Hegde, Ph.D., is Senior Vice President and Head of Research at Theravance Biopharma. Prior to joining Theravance in 1999, Dr. Hegde spent 9 years at Syntex Corporation, later acquired by Roche. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Mumbai in India.
>
> Dr. Hegde has over 28 years of leadership experience in strategic and tactical aspects of drug-discovery. In his current position at Theravance Biopharma, Dr. Hegde leads a group of chemists, pharmacologists, biologists and pharmacokineticists towards the discovery of novel small-molecule medicines for unmet medical needs. Dr. Hegde has been trained in classical ‘integrated pharmacology’. He possesses extensive experience in seeding new project ideas and designing preclinical studies to test hypothesis and enable discovery of first-in-class/best-in-class drugs in multiple therapeutic areas including infectious, cardiovascular, respiratory, genitourinary, gastrointestinal, CNS, fibrotic, autoimmune and inflammatory diseases. He has participated in the discovery of several NCEs at Syntex/Roche and Theravance Biopharma, including the antiemetic Aloxi® (palonosetron), antibiotic Vibativ® (telavancin), Revefenancin (bronchodilator currently in pre-registration for COPD), Axelopran (Phase 2 for opioid induced constipation), Velusetrag (Phase 2 for gastroparesis) and TD-9855 (Phase 2 for neurogenic orthostatic hypotension).
>
> Dr. Hegde is the co-author of over 50 scientific publications. He has served on the editorial board of Naunyn Schmiedeberg’s Archives of Pharmacology and as a member of the Scientific Advisory Board of Keystone Symposia.
>
> When: Thursday, February 15, 2018
>>
>> 6:30pm - 7pm Networking mixer
>> 7pm - 8:30pm Spotlight Speaker Presentation followed by Q&A
> Where: Sheppard Mullin, 379 Lytton Ave, Palo Alto, CA 94301
>
> Registration is complimentary. Food and Refreshments will be provided. As seating is limited, please arrive on time to reserve your spot.